Eli Lilly: positive results for breast cancer drug

(CercleFinance.com) - Eli Lilly shares were one of the leaders in the S&P 500 Index on Tuesday morning on the New York Stock Exchange following the announcement of positive results from a trial of a new breast cancer treatment.
At 9:35 a.m. New York time, the stock was up over 10%, while the S&P was up 2.4% in comparison.

The US laboratory has reported that data from a Phase 3 clinical trial has showed that Verzenio reduced the risk of recurrence in patients with early-stage HR+/HER2- breast cancer at high risk of recurrence.

HR+, HER2- cancers account for about 70% of breast cancers, according to Eli Lilly.

Verzenio is a kinase inhibitor, a type of drug that prevents cancer cells from dividing and spreading.


Copyright (c) 2020 CercleFinance.com. All rights reserved.